Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatology Research Foundation Advances Studies in Inflammatory Arthritis

Staff  |  Issue: October 2013  |  October 1, 2013

Foundation News
The Foundation has awarded 101 Disease Targeted Research Initiative grants.

Advancing Targeted Research

As one important step in achieving its mission to advance research and training in rheumatology to help improve the health of people with rheumatic diseases, the Rheumatology Research Foundation launched its Disease Targeted Research Initiative seven years ago. In that span, the Foundation has awarded 101 pilot and innovative research grants, totaling $43.2 million, to investigators exploring aspects of rheumatoid arthritis (RA) and other forms of inflammatory disease.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

On June 21–23 at the Fairmont Hotel in Dallas, the Rheumatology Research Foundation gathered a group of these investigators to present their latest findings. In addition to poster presentations, 22 investigators from institutions around the U.S. had the opportunity to engage in collaborative discussions surrounding inflammatory disease. Live sessions included presentations on drug clinical trial updates, cardiovascular risk in RA, epigenetics, outcome measures and quality, disease pathogenesis, pathways of inflammation, and other topics.

Based on the quality of the research presented at the meeting and the positive response from many attendees, the Investigators Meeting was “an unqualified success,” says David Daikh, MD, PhD, the Foundation’s President. “The relatively small and intimate meeting provided investigators focused on a single and important topic—inflammatory arthritis—the opportunity to share and discuss new ideas.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The research presented at the Dallas meeting will not just be of interest to rheumatologists, but will also resonate with the patient community, as it may generate more effective treatments and preventive measures in RA, says Dr. Daikh. “For example, new understanding about the role of gingivitis in disease activity in rheumatoid arthritis has important implications in developing new ways of preventing disease and decreasing disease activity,” he says. “Similarly, results from a new clinical trial funded by the Foundation may show how to identify the development of cardiovascular disease in patients with inflammatory arthritis in time to initiate preventive therapy.”

Even though the Disease Targeted Research Initiative is only a few years old, the results of the Foundation’s commitment to these investigators already reveal important data that will one day help rheumatologists and their patients better tackle these diseases, says David Karp, MD, PhD, the Foundation’s Vice President. Success breeds success, with exciting findings sparking further studies, he adds.

“These meetings have become a highlight of the program, as the top researchers in the field get a chance to share their findings and discuss new projects. The meetings are small, and allow for a lot of informal discussion and cross-fertilization of ideas. Even though the program is still relatively young, we have seen ideas for newly funded projects spring from previous meetings,” says Dr. Karp.

When the Foundation launched this initiative, it sought to find “the best, most innovative projects and give them enough funding to move … to the next level,” Dr. Karp adds. Grant applicants included researchers outside of rheumatology and those new to RA research. “Of our 101 funded investigators, 87 have gone on to secure [a total of] $187 million in NIH funding. They have published 200 articles and delivered over 300 presentations on their Rheumatology Research Foundation–funded work,” says Dr. Karp.

One of the investigators presenting his findings at the meeting, Michael Holers, MD, says this extraordinarily important program will help rheumatologists discover new ways to treat their RA patients.

“Support from the Foundation has been critical to those of us who are interested in figuring out how rheumatoid arthritis starts in individuals who demonstrate highly related antibodies, but who are initially asymptomatic for several years prior to subsequently developing pain and swelling,” says Dr. Holers, a rheumatologist at the University of Colorado, Denver. “In this area of exploratory high-risk, high-reward research, continued support of the Foundation has the real potential to lead to prevention of the development of this disease.”

The exciting results of the Dallas investigators meeting highlight the importance of the Foundation’s continuing support for its disease-targeted research efforts, says Dr. Daikh. Unearthing the causes of rheumatic diseases, developing new treatments, and possibly finding a cure for these patients will only come from long-term commitment to fundamental research and training, he says.

“A strong academic research community has been the backbone of rheumatology training programs across the country. The ongoing work and survival of a strong research community is absolutely vital to ensure future discoveries and to the ongoing health of rheumatology training programs,” says Dr. Daikh. “Support of these investigators through the funds given to the Foundation is of great importance to patients and to the rheumatology community as a whole.”

For more information on the Rheumatology Research Foundation or to learn more about the Disease Targeted Research program, please call (404) 633-3777 or visit www.rheumatology.org/foundation.

Page: 1 2 | Multi-Page
Share: 

Filed under:From the CollegeResearch Rheum Tagged with:foundationInflammatory arthritisResearchRheumatoid arthritisrheumatology

Related Articles

    Incoming ACR President David Karp, MD, PhD, Eager to Move Forward on Workforce Shortage, Workplace Bias & Member Engagement

    November 6, 2020

    With extensive leadership experience in practice and through many roles with the ACR’s committees, executive board of directors and Rheumatology Research Foundation, Dr. Karp is ready to address workforce shortages, workplace bias and member engagement to ensure a strong future for the College through COVID-19 and beyond.

    Rheumatology Research Foundation Backs Need to Accelerate New Medicines for Lupus

    November 1, 2014

    Foundation appeals to Congressional lawmakers for support of biomedical innovation to battle lupus

    Meet Dr. David Daikh—the ACR’s New President

    October 31, 2017

    This month, the ACR ushers in its new president, David Daikh, MD, PhD. Dr. Daikh serves as the director of the Rheumatology Fellowship Training Program at the University of California, San Francisco (UCSF) and as chief of the Rheumatology Division at the SFVA Medical Center, where he directs the Rheumatology Clinic. He graduated from the Oregon…

    When Rheumatology Becomes a Family Affair

    March 17, 2018

    Father and daughter, Len Calabrese, DO, FACR, and Cassie Calabrese, DO Rheumatologists spend so many years treating the same patients, sometimes they start to feel like family. But for some doctors, it’s more than a feeling. The specialty attracts its fair share of relatives who can compare rheumatic notes, discuss complex cases and provide a…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences